- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: Phakic IOL Implantation II
Session Date/Time: Wednesday 09/10/2013 | 08:00-10:30
Paper Time: 08:00
Venue: E104-105 (First Floor)
First Author: : J.Cazal SPAIN
Co Author(s): : F. Sanchez Fabo
To evaluate the safety, efficacy, predictability, stability, and complications of the foldable Artiflex Toric iris-fixated intraocular lens and Artisan Toric (Ophtec BV, Groningen, The Netherlands) for the correction of myopia and astigmatism in phakic eyes
Centro Oftalmológico del Bages, Manresa,Spain
All eyes underwent implantation of the foldable iris-fixated Artiflex phakic intraocular lens (PIOL) with an optic zone of 6 mm. The follow-up was 3 years. Phakic intraocular lenses were implanted in powers ranging from -6.0 to -14.0 D.
After 3 years, a UCVA of 20/40 or better was observed in 96.2% of eyes. The BSCVA was 20/40 or better in all eyes. A gain of 1 line or more of BSCVA was found in 40.9% of eyes, and none lost 2 or more lines. The mean endothelial cell change was -0.05%, 1.89%, and -2.7% at 6 months, 1 year, and 2 years,respectively. Chronic inflammation was not detected in any eye by slit-lamp biomicroscopy, nor did any eye develop angle closure or glaucoma.
After 3 years of follow-up results suggest that the Artisan/Artiflex lens is an accurate and safe method for the correction of myopia and astigmatism. Surgical skill is important but could be performed by novel surgeons. Longer-term data are needed to assess the impact of the lens on the endothelium, the crystalline lens, and the iris
Please wait while information is loading.